Johnny Hu
Principal at Menlo Ventures
San Francisco Bay Area
Overview
Work Experience
Principal
2021 - Current
Menlo Ventures provides capital for consumer, enterprise, and life science technologies from seed to growth stages.
Board Observer
2020 - 2021
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
Raised $295,500,000.00 from Tekla Capital Management, Fidelity, Ally Bridge Group, Invus, AyurMaya, Longitude Capital, Piper Heartland Healthcare Capital, T. Rowe Price, Omega Funds and Velosity Capital.
Board Observer
2020 - 2021
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
Raised $280,000,000.00 from Surveyor Capital, Eventide, RA Capital Management, Braidwell, Novo Holdings and Adage Capital Management.
Vice President
2019 - 2021
Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Associate
2018 - 2019
Omega Funds global life sciences-based investment firm that specializes in direct secondary transactions.
Fellow
2017 - 2018
Vida Ventures is a next-generation life sciences investment firm .
President
2015 - 2017
Intern
2017 - 2017
Associate Intern
2015 - 2015
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Research Oncology
2011 - 2011
Genentech specializes in genetic testing and personalized medicine.
Education
Doctor of Philosophy (PhD)
2012 - 2018
MPhil
2011 - 2012
Bachelor of Arts
2007 - 2011